Cornerstone Pharmaceuticals Inc., of Cranbury, N.J., reported that for 20 patients with stage IV pancreatic adenocarcinoma enrolled in its phase I study of CPI-613 in combination with Folfirinox, there was an objective response rate of 56 percent, higher than what has been reported for Folfirinox alone (31.6 percent).